Schneeweiss Andreas, Fasching Peter A, Fehm Tanja, Gerber Bernd, Jackisch Christian, Loibl Sibylle, Schmidt Marcus, Stickeler Elmar, Wöckel Achim, Janni Wolfgang, Müller Volkmar
Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany.
Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1101-1111. doi: 10.1055/a-1519-7089. Epub 2021 Oct 6.
Therapy options shown in the algorithms are based on the current AGO recommendations, but cannot represent all evidence-based treatment options, since prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. In individual cases, other evidence-based treatment options may also be appropriate and justified. Regardless of approval status, the algorithms only take into account drugs that were available in Germany at the time the algorithm was last updated. Here we present the 2021 update of AGO treatment algorithms for early and metastatic breast cancer, which are intended to intensify structured treatment decision by providing reproducible and evidence-based treatment paths and may be helpful for a broad treatment landscape.
算法中所示的治疗方案基于AGO当前的建议,但不能代表所有循证治疗方案,因为实际治疗选择必须考虑既往治疗、身体状况、合并症、患者偏好等因素。在个别情况下,其他循证治疗方案也可能是合适且合理的。无论批准状态如何,算法仅考虑在算法最后更新时德国可用的药物。在此,我们展示AGO早期和转移性乳腺癌治疗算法的2021年更新版,其旨在通过提供可重复且循证的治疗路径来强化结构化治疗决策,可能有助于构建广泛的治疗格局。